Valuation: Evolus, Inc.

Market Cap 554M 475M 444M 407M 763M 53.02B 773M 5.25B 2.05B 26.64B 2.08B 2.04B 88.1B P/E 2026 *
-17.5x
P/E 2027 * -51.4x
Enterprise Value 675M 578M 541M 495M 930M 64.6B 942M 6.39B 2.49B 32.45B 2.54B 2.48B 107B EV / Sales 2026 *
2.02x
EV / Sales 2027 * 1.74x
Free-Float
81.64%
Yield 2026 *
-
Yield 2027 * -
1 day+0.48%
1 week+2.88%
Current month+43.66%
1 month+40.07%
3 months+37.77%
6 months+93.76%
Current year+26.17%
1 week 7.81
Extreme 7.81
8.69
1 month 5.72
Extreme 5.7201
8.69
Current year 3.86
Extreme 3.86
8.69
1 year 3.86
Extreme 3.86
8.69
3 years 3.86
Extreme 3.86
17.82
5 years 3.86
Extreme 3.86
17.82
10 years 2.85
Extreme 2.85
39.5
Manager TitleAgeSince
Chief Executive Officer 48 06/05/2018
Director of Finance/CFO 48 08/09/2025
Chief Operating Officer - 01/09/2022
Director TitleAgeSince
Chairman 63 01/01/2018
Director/Board Member 71 12/02/2018
Director/Board Member 48 06/05/2018
Date Insider Type Main position Quantity % Market Cap.
16/3/26 Fiscal year

Chief Executive Officer

251,698 0.3891%
17/2/26 Free

Chief Financial Officer

420,449 0.6500%
17/2/26 Free

Chief Technology Officer

328,475 0.5078%
Change 5-day change 1-year change 3-year change Capi.($)
+0.48%+2.88%+9.24%-9.10% 554M
+0.88%+6.38%+76.40%+126.87% 1,119B
+1.07%+3.80%+50.73%+64.25% 651B
+1.20%+6.21%+25.81%+80.15% 468B
-1.24%+4.24%+42.82%+42.69% 374B
-0.29%+2.98%+25.52%+41.42% 302B
-0.74%+4.91%+2.16%+12.82% 259B
+1.29%+5.81%+49.57%+70.71% 238B
+0.57%+3.44%-17.66%-53.17% 208B
+1.87%+5.61%+27.32%+89.67% 181B
Average +0.51%+4.94%+29.19%+46.63% 380.04B
Weighted average by Cap. +0.60%+5.40%+44.19%+72.39%

Financials

2026 *2027 *
Net sales 334M 286M 268M 245M 460M 31.95B 466M 3.16B 1.23B 16.05B 1.25B 1.23B 53.08B 391M 335M 313M 287M 538M 37.4B 545M 3.7B 1.44B 18.79B 1.47B 1.44B 62.14B
Net income -32.36M -27.72M -25.94M -23.74M -44.56M -3.1B -45.15M -306M -119M -1.56B -122M -119M -5.14B -10.14M -8.69M -8.13M -7.44M -13.97M -971M -14.15M -96.07M -37.46M -488M -38.09M -37.26M -1.61B
Net Debt 121M 104M 96.98M 88.78M 167M 11.58B 169M 1.15B 447M 5.82B 454M 444M 19.24B 126M 108M 101M 92.44M 173M 12.06B 176M 1.19B 465M 6.06B 473M 463M 20.03B
Logo Evolus, Inc.
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
Employees
353
Date Price Change Volume
21/08/26 USD 8.390 +0.48% 582,721
20/08/26 USD 8.350 -2.91% 663,320
19/08/26 USD 8.600 +5.13% 964,004
18/08/26 USD 8.180 +5.28% 710,440
17/08/26 USD 7.770 -4.72% 614,480
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
8.390USD
Average target price
15.00USD
Spread / Average Target
+78.78%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EOLS Stock